GM-CSF restoration of a differentiated (growth factor-regulated) phenotype in an anaplastic tumor

M. Rubenstein; M. Shaw; P. Targonski; C. F. McKiel; A. Dubin; P. Guinan

doi:10.1007/BF00299066

GM-CSF restoration of a differentiated (growth factor-regulated) phenotype in an anaplastic tumor

M. Rubenstein, M. Shaw, P. Targonski, C. F. McKiel, A. Dubin, P. Guinan

Primary Care Internal Medicine

Research output: Contribution to journal › Article

2 Scopus citations

Abstract

GM-CSF (granulocyte-macrophage-derived colony-stimulating factor) is a differentiation agent that stimulates bone marrow activity in patients receiving chemotherapy. GM-CSF (1 μg/ml daily for 10 days), administered intralesionally, was evaluated to determine whether it would restore a more differentiated phenotype to an anaplastic, rapidly growing, hormone-independent variant (R3327 MAT-LyLu) of the Dunning prostatic adenocarcinoma. Immunohistology was used to quantitate the expression of epithelial growth factor receptors (rEGF) and the tissue testosterone content. GM-CSF therapy significantly (P<0.05) restored rEGF expression and tissue testosterone to levels associated with better differentiated, slower growing, androgen-dependent Dunning variants (R3327 H and G). GM-CSF may have a role in treatment of prostatic cancers by promoting androgen and epithelial growth factor regulation.

Original language	English (US)
Pages (from-to)	309-312
Number of pages	4
Journal	Urological Research
Volume	19
Issue number	5
DOIs	https://doi.org/10.1007/BF00299066
State	Published - Sep 1 1991

Keywords

Differentiation
Dunning tumor
GM-CSF
Growth factors
Prostate
Therapy

ASJC Scopus subject areas

Urology

Access to Document

10.1007/BF00299066

Fingerprint Dive into the research topics of 'GM-CSF restoration of a differentiated (growth factor-regulated) phenotype in an anaplastic tumor'. Together they form a unique fingerprint.

Cite this

Rubenstein, M., Shaw, M., Targonski, P., McKiel, C. F., Dubin, A., & Guinan, P. (1991). GM-CSF restoration of a differentiated (growth factor-regulated) phenotype in an anaplastic tumor. Urological Research, 19(5), 309-312. https://doi.org/10.1007/BF00299066

@article{c559713779404537a5a804758d013c47,

title = "GM-CSF restoration of a differentiated (growth factor-regulated) phenotype in an anaplastic tumor",

abstract = "GM-CSF (granulocyte-macrophage-derived colony-stimulating factor) is a differentiation agent that stimulates bone marrow activity in patients receiving chemotherapy. GM-CSF (1 μg/ml daily for 10 days), administered intralesionally, was evaluated to determine whether it would restore a more differentiated phenotype to an anaplastic, rapidly growing, hormone-independent variant (R3327 MAT-LyLu) of the Dunning prostatic adenocarcinoma. Immunohistology was used to quantitate the expression of epithelial growth factor receptors (rEGF) and the tissue testosterone content. GM-CSF therapy significantly (P<0.05) restored rEGF expression and tissue testosterone to levels associated with better differentiated, slower growing, androgen-dependent Dunning variants (R3327 H and G). GM-CSF may have a role in treatment of prostatic cancers by promoting androgen and epithelial growth factor regulation.",

keywords = "Differentiation, Dunning tumor, GM-CSF, Growth factors, Prostate, Therapy",

author = "M. Rubenstein and M. Shaw and P. Targonski and McKiel, {C. F.} and A. Dubin and P. Guinan",

year = "1991",

month = sep,

day = "1",

doi = "10.1007/BF00299066",

language = "English (US)",

volume = "19",

pages = "309--312",

journal = "Urolithiasis",

issn = "2194-7228",

publisher = "Springer Verlag",

number = "5",

}

TY - JOUR

T1 - GM-CSF restoration of a differentiated (growth factor-regulated) phenotype in an anaplastic tumor

AU - Rubenstein, M.

AU - Shaw, M.

AU - Targonski, P.

AU - McKiel, C. F.

AU - Dubin, A.

AU - Guinan, P.

PY - 1991/9/1

Y1 - 1991/9/1

N2 - GM-CSF (granulocyte-macrophage-derived colony-stimulating factor) is a differentiation agent that stimulates bone marrow activity in patients receiving chemotherapy. GM-CSF (1 μg/ml daily for 10 days), administered intralesionally, was evaluated to determine whether it would restore a more differentiated phenotype to an anaplastic, rapidly growing, hormone-independent variant (R3327 MAT-LyLu) of the Dunning prostatic adenocarcinoma. Immunohistology was used to quantitate the expression of epithelial growth factor receptors (rEGF) and the tissue testosterone content. GM-CSF therapy significantly (P<0.05) restored rEGF expression and tissue testosterone to levels associated with better differentiated, slower growing, androgen-dependent Dunning variants (R3327 H and G). GM-CSF may have a role in treatment of prostatic cancers by promoting androgen and epithelial growth factor regulation.

AB - GM-CSF (granulocyte-macrophage-derived colony-stimulating factor) is a differentiation agent that stimulates bone marrow activity in patients receiving chemotherapy. GM-CSF (1 μg/ml daily for 10 days), administered intralesionally, was evaluated to determine whether it would restore a more differentiated phenotype to an anaplastic, rapidly growing, hormone-independent variant (R3327 MAT-LyLu) of the Dunning prostatic adenocarcinoma. Immunohistology was used to quantitate the expression of epithelial growth factor receptors (rEGF) and the tissue testosterone content. GM-CSF therapy significantly (P<0.05) restored rEGF expression and tissue testosterone to levels associated with better differentiated, slower growing, androgen-dependent Dunning variants (R3327 H and G). GM-CSF may have a role in treatment of prostatic cancers by promoting androgen and epithelial growth factor regulation.

KW - Differentiation

KW - Dunning tumor

KW - GM-CSF

KW - Growth factors

KW - Prostate

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=0025787553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025787553&partnerID=8YFLogxK

U2 - 10.1007/BF00299066

DO - 10.1007/BF00299066

M3 - Article

C2 - 1949430

AN - SCOPUS:0025787553

VL - 19

SP - 309

EP - 312

JO - Urolithiasis

JF - Urolithiasis

SN - 2194-7228

IS - 5

ER -